Boston University School of Medicine designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Eisai Inc.
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices is being discussed.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration.
Dr Apovian: advisory board: Arena Pharmaceuticals, Inc., EnteroMedics Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Nutrisystem, Zafgen; advisory board/research grants: Amylin Pharmaceuticals, LLC, Orexigen Therapeutics, Inc., sanofi-aventis; research grants: Aspire Bariatrics, LLC, The Dr. Robert C. and Veronica Atkins Foundation, Eli Lilly and Company, GI Dynamics, MetaProteomics, Pfizer Inc.
Dr Aronne: advisory board/consultant: Arena Pharmaceuticals, Inc., Eisai Inc., Ethicon Endo-Surgery, Inc., GlaxoSmithKline, Orexigen Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Vivus Inc., Zafgen; advisory board/consultant/research grants: Amylin Pharmaceuticals, LLC, Novo Nordisk A/S; board of directors/ownership interest:Myos Corporation; ownership interest: Cardiometabolic Support Network, LLC, Zafgen; research grants: Aspire Bariatrics, LLC, GI Dynamics, High Point Pharmaceuticals, LLC, Medical University of South Carolina.
Dr Fujioka: consultant: Isis Pharmaceuticals, Inc., Zafgen; consultant/research grants: Novo Nordisk A/S, Orexigen Therapeutics, Inc.; consultant/research grants/speakers bureau: Eisai Inc., NPS Pharmaceuticals, Inc.; research grants: EnteroMedics Inc., Shire, Weight Watchers International, Inc.; speakers bureau: Abbott Laboratories, Merck & Co., Inc.
Dr Kushner: consultant: Novo Nordisk A/S, Retrofit, Inc., Vivus Inc.; research grants: Aspire Bariatrics, LLC, Weight Watchers International, Inc.
The Planning Committee for this activity included Mike Burk of Boston University School of Medicine; and Ruth Cohen and Christie Avraamides, PhD of Continuing Education Alliance. The members of the Planning Committee have no significant relationships to disclose.
The following agents may be discussed off-label: bupropion, GLP-1 inhibitors, metformin, and SGLT-2 inhibitors. DISCLAIMER
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTHCARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.